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Abstract
Previous studies have demonstrated the involvement of complement (C) in induction of efficient CTL responses against
different viral infections, but the exact role of complement in this process has not been determined. We now show that C
opsonization of retroviral particles enhances the ability of dendritic cells (DCs) to induce CTL responses both in vitro and in
vivo. DCs exposed to C-opsonized HIV in vitro were able to stimulate CTLs to elicit antiviral activity significantly better than
non-opsonized HIV. Furthermore, experiments using the Friend virus (FV) mouse model illustrated that the enhancing role
of complement on DC-mediated CTL induction also occurred in vivo. Our results indicate that complement serves as natural
adjuvant for DC-induced expansion and differentiation of specific CTLs against retroviruses.
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Introduction
During the acute phase of HIV-1 infection the immune system
responds with a massive, oligoclonal expansion of CD8
+ T cells
[1]. The appearance of virus-specific CTLs correlates with
declining viremia during this acute phase of infection, but CTLs
are not associated with control of the virus during the chronic
phase [2,3]. Ongoing HIV infection induces a sustained
inflammatory response and causes progressive functional defects
in CTL populations [4]. A gradual failure of the immune response
occurs due to a dramatic loss of CD4
+ T cells, spontaneous
apoptosis of non-infected, activated CD4
+ and CD8
+ T cells,
induction of Tregs, escape of virus-specific CD8
+ T cell recognition
by HIV, and destruction of the follicular dendritic cell network [5].
In long-term non-progressors HIV-specific CTLs are suggested to
be important mediators of protection due to increased anti-HIV
CTL precursor numbers and lower viral burden [6].
Increasing evidence suggests an important role for the
complement system in protection against viral infections. For
example, C activation contributes not only directly to host
protection against viruses by C-mediated lysis or opsonization,
but is also essential in priming humoral responses as demonstrated
for different viral infections [7–9]. More recently, the involvement
of the complement system in priming antiviral T cell immunity
was highlighted [10–12]. Upon infection of C3-deficient mice with
influenza virus, a significant impairment in priming of CD4
+
helper cells and virus-specific cytotoxic T lymphocytes was
observed, which resulted in delayed clearance of the infection
and increased viral titers [10]. Similarly, the induction and
expansion of CD8
+ T cells during infection with lymphocytic
choriomeningitis virus (LCMV) depended on C3 [11]. A further
study investigating West Nile virus (WNV) infection in mice
deficient for different complement components revealed that the
activation of both classical and alternative pathways was required
to induce an efficient T cell response [12]. In line with these
observations, C3 together with natural antibodies could act as an
endogenous adjuvant for vaccine-induced T cell responses [13].
In HIV-1 infections, virions activate the complement system,
and are already coated with C fragments at the initial stages of
infection [14,15]. We recently demonstrated that compared to
non-opsonized virus, C-coating of HIV-1 significantly enhanced
the infection of DCs in vitro through complement receptor type 3
(CR3, CD11b/CD18) and CR4 (CD11c/CD18), which also
resulted in a different internalization pattern [14,16]. Thus, C-
opsonization of retroviruses could have profound consequences on
the antigen-presenting capacity of DCs and the subsequent
immune response.
Since it is extremely difficult to investigate the role of HIV-
complement interactions on the induction of virus-specific CTLs in
vivo we used the well-characterized Friend virus (FV) mouse model
for in vivo studies. FV is a retroviral complex consisting of two
viruses: a non-pathogenic replication-competent helper virus
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replication-defective spleen focus-forming virus (SFFV) [17].
Infection of adult mice with this complex results in polyclonal
proliferation of erythroid precursor cells causing massive spleno-
megaly. Disease progresses to lethal erythroleukemia in susceptible
mouse strains, whereas resistant mouse strains are able to control,
but never completely eradicate infection. A chronic infection
develops, which is associated with the induction of Tregs that
suppress effector functions of virus-specific CTLs [18,19].
Here, we found that DCs exposed to C-opsonized HIV induced
a more pronounced and functional virus-specific CD8
+ T cell
response in vitro compared to the priming with DCs exposed to
non-opsonized HIV. This DC-mediated, C-dependent priming of
virus-specific CTLs was confirmed in vivo using the FV model. Our
in vitro and in vivo observations provide the first evidence that DCs
along with complement opsonization account for effective CTL
induction upon viral infections.
Results
Repeated prime-boosting with HIV-C-exposed DCs
triggers CD8
+ T cell proliferation
Naive CD8
+ T cells were primed-boosted three times with loaded
DCs to determine if complement opsonization of HIV exerted an
influence on the antigen-presenting capacity of DCs. To mimic the
in vivo situation, where HIV is opsonized with complement
fragments at the beginning of infection, we opsonized live virus
with complement (HIV-C) prior to incubation with cytokine-
stimulated monocyte-derived DCs. The effect of HIV-C on DCs
was compared to DCs exposed to non-opsonized HIV (HIV) or
HIV opsonized with complement-inactivated serum (HIV-hiC) to
confirm the complement-mediated effects and exclude other factors
possibly present in serum such as natural Abs. The opsonization
pattern of the single HIV-preparations is shown in Supplementary
Figure S1A. Furthermore, DCs stimulated with either superantigen
Staphylococcal Enterotoxin B (SEB-DCs) or a cytokine-cocktail (IL-
1b,I L - 6 ,T N F - a,P G E 2) (mDCs) and immature DCs (iDCs) were
also included in the experiments. Analysis of relative CD8
+ Tc e l l
concentrations showed that DCs loaded with complement-opson-
ized HIV triggered significantly more proliferation than those
loaded with non-opsonized HIV (p=0.0141) (Fig. 1A) and HIV-Ig
or HIV-hiC (not shown). The CD8
+ T cell proliferation induced by
cytokine-stimulated mDCs, which served as control for the HIV- or
HIV-C-mediated effects, was intermediate and significantly lower
than that mediated by HIV-C-DCs (p=0.0259), but not HIV-DCs
(not significant, ns) (Fig. 1A). CD8
+ T cell proliferation induced by
cytokine-stimulated mDCs and iDCs were included as negative
controls (Fig. 1A). Fig. 1A summarizes the relative mean expansion
of CD8
+ T cells from 5 donors and two different virus strains (BaL,
92UG037). Since using live virus and cultivating DCs after exposure
to HIV in co-culture with the CD8
+ T cells, we excluded that the
HIV-C-DC-mediated expansion of CD8
+ T cells was exclusively
due to a better productive infection of the DCs compared to HIV-
DCs. We previously reported that C-opsonization of HIV enhances
D Ci n f e c t i o na tl e a s t2t o3 - f o l dc o m p a r e dt on o n - o p s o n i z e dH I V
[14,16]. Thus, the prime-boost experiment was additionally
performed using same DC loading concentrations (25 ng p24/ml)
as live virus of non-/hiC- or C-opsonized AT2-inactivated R5-
(92UG037) and R5X4 (93BR020)-tropic HIV-1 preparations.
Following three prime-boost cycles, DCs loaded with AT2-
inactivated HIV-C induced significantly greater CD8
+ Tc e l l
proliferation than DCs loaded with AT2-inactivated, non-opsonized
HIV (Fig. 1B). However, the expansion of CD8
+ T cells mediated
by DCs loaded with AT-2-inactivated HIV-C was lower than that
induced by DCs loaded with live HIV-C (compare Fig. 1A and 1B).
CD8
+ T cell proliferation was also analyzed by labeling cells with
CFSE prior to the first priming with loaded DCs. Flow cytometric
analyses confirmed that stimulation by DCs loaded with comple-
ment-opsonized HIV induced significantly greater proliferation of
CD8
+ T cells compared to non-opsonized HIV or HIV-hiC (Figure
S1B). Representative dot plots (Fig. 1C, left panel) and mean data
(Fig. 1C, right panel) showed that HIV-C-DCs mediated signif-
icantly increased T cell expansion that was at least 4-fold higher
compared to HIV-DCs, which induced only a low proliferation rate.
IFN-c secretion is increased in CD8
+ T cell cultures after
repeated stimulation with C-HIV loaded DCs
Since IFN-c is a cytokine predominantly secreted by activated
CD8
+ and CD4
+ effector T cells, we next tested whether the
expanded CD8
+ T cells secreted IFN-c after repeated priming
with loaded DCs. HIV-C-loaded DCs induced significantly higher
IFN-c secretion by CD8
+ T cell cultures compared to HIV-loaded
DCs, which produced no significant IFN-c above control iDCs
(Fig. 2A). The results obtained by ELISA were confirmed by an
IFN-c secretion assay, which showed that HIV-C-DC-boosted
CD8
+ T cells secreted increased amounts of IFN-c compared to
HIV-DC-boosted CD8
+ T cells (Fig. 2B).
HIV-C-DC-primed CD8
+ T cells are antigen-specific
Next we used tetramer analysis to determine whether the DC-
stimulated CD8
+ T cells were HIV-specific. CD8
+ T cells from an
HLA-A02
+ donor were expanded by stimulation with the differen-
tially loaded DCs and then re-stimulated with HLA-A02-restricted
HIV-specific (P1) and control (P2) peptides in the presence of CD3/
CD28 beads and IL-2 (100U/ml). We gated on live CD8
high Tc e l l s .
Only a very small proportion of HIV-hiC(X4)- (Fig. 3A) or HIV(X4)
(not shown)-DC-primed CD8
+ T cells reacted with the tetramer
(0.1%) whereas 7.6% of the HIV-C(X4)-DC-primed CD8
+ T cells
stained positive following stimulation with the HLA-A02-restricted
HIV-specific peptide P1 (Fig. 3A, HIV-C(X4)). In contrast, upon
stimulation of HIV-C(X4)-DC-primed CD8
+ T cells with the control
HIV peptide P2 only 1.1% of the cells were stained positive for the
Author Summary
Upon entering the body, HIV initiates immediate respons-
es of the immune system. The complement system
constitutes a first line of defense against HIV and bridges
innate and adaptive immunity. Thus, in the acute phase of
infection, HIV is coated with complement fragments.
Following seroconversion, when HIV-specific antibodies
appear, antibodies and complement are deposited onto
HIV. Dendritic cells (DCs), the most potent antigen-
presenting cells, interact with complement- and Ig-
opsonized HIV due to expression of the appropriate
receptors. Recently, we found differences with respect to
infection of DCs with complement- and Ig-opsonized HIV.
We have now investigated whether these differently
opsonized HIV preparations also modulated the antigen-
presenting capacity of DCs. Since it is extremely difficult to
investigate the role of HIV-complement interactions on the
induction of virus-specific cytotoxic T lymphocytes (CTLs)
in vivo, we used the well-characterized Friend virus (FV)
mouse model for our in vivo studies. We now show that
complement opsonization of retroviral particles enhanced
the ability of DCs to induce CTL responses against HIV or
FV. Thus, our results indicate that complement serves as
natural adjuvant for DC-induced expansion and differen-
tiation of specific CTLs against retroviruses.
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exposed DCs induced 14.2% and 7.2% tetramer positive CD8
+ T
cells upon specific stimulation, respectively (Fig. 3A, HIV-C(R5X4),
HIV-C(R5)). Again HIV(R5X4 and R5)-DCs mediated only a low
amount (1.4%) of tetramer positive CD8
+ T cells (not shown). In
control experiments, CD8
+ T cells primed/boosted with cytokine-
stimulated mDCs and P1 (Fig. 3A, Control (mDCs)) or P2 (not
shown) were analyzed for tetramer-positive cells. Only a small
percentage of the mDC-stimulated T cells were tetramer positive
(1.5%), which was comparable to that also observed after stimulation
of HIV(X4)-C-DC-primed CD8
+ T cells with the control peptide P2.
HIV-C-DC-primed and expanded CTLs degranulate upon
stimulation with HIV-gag peptides
Next, we assessed the ability of the in vitro generated and CD3/
CD28-expanded CD8
+ T cells to degranulate in response to Ag-
specific stimulation [20]. By measuring CD107a-mobilization to
the cell surface, which occurs upon fusion of the cytolytic
membrane, degranulation can be detected by flow cytometry. In
all experiments SEB was used as a positive control [21], and a
negative control was included to control for spontaneous
expression of CD107a. HIV-C-DC-primed CD8
+ T cells showed
significantly greater degranulation upon recognition of the HIV-
specific P1 peptide than T cells primed with non-opsonized HIV
(Fig. 3B). Degranulation was independent of the tropism of the
HIV isolates (Fig. 3B).
HIV-C-DC primed CD8
+ T cells elicit anti-HIV-activity
To further characterize the functionality of the in vitro generated
CD8
+ T cells, expanded T cells were added to autologous, infected
CD4
+ T cells. Supernatants were taken on several days after co-
culture for measurement of p24 by ELISA. The amount of p24
Figure 1. Proliferation of HIV-C-DC-primed CD8
+ Tc e l l s .Complement-opsonization of HIV (A) or AT2-inactivated HIV (B) and subsequent loading
of DCs initiates proliferation of CD8
+ T cells as measured by counting CD8
+ T cells over a one minute period of time (A) and by CFSE-staining of CD8
+ T
cells (C). As positive control, DCs were exposed to the superantigen SEB, which induced strong proliferation of CD8
+ T cells. The response to SEB was set
at 100%. (A) No or low proliferation comparable to iDC-primed CD8
+ T cells was mediated by DCs exposed to non-opsonized HIV (HIV). Cytokine-
stimulated mDC-primed CD8
+ T cells showed low proliferation, while HIV-C-exposed DCs induced about 60% proliferation compared to SEB-DC-primed
CD8
+ T cells. Columns represent mean values of CD8
+ T cells from 5 donors stimulated with either BaL or 92UG037. Data were analyzed by unpaired
Student’s t-test. (B) Prime-boosting by AT2-HIV-C-loaded DCs caused proliferation of autologous CD8
+ T cells, albeit weaker than with HIV-C-exposed
DCs. In contrast, DCs loaded with AT2-HIV did not induce proliferation of CD8
+ T cells at all. This was repeated four times with HIV strains 92BR030 or
92UG037. (C) Complement-mediated proliferation of CD8
+ T cells was confirmed with 5 donors by staining cells with 2.5 mM CFSE prior addition of
loaded DCs (n=5). Left panel: dot plot of CD8
+ T cells exposed three times to SEB-, HIV- or HIV-C-loaded DCs, and a CFSE
+ control. The amount of cells in
the live CD8
high population (P3) is shown in the dot plot for one representative donor. Right panel: mean percentages of CFSE
2 [proliferated]/CD8
+ T cells
of SEB-, HIV- or HIV-C-DC-primed CD8
+ T cells from 5 donors. Data were analyzed by unpaired Student’s t-test.
doi:10.1371/journal.ppat.1000891.g001
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infection of the CD4
+ T cells indicates an anti-viral effect by the
generated CD8
+ cells.
Indeed, CD8
+ T cells boosted three times with HIV-C exerted
anti-HIV-activity against NL4-3-infected CD4
+ T cells as the
cultures showed a significantly lower p24 value than HIV-infected
Figure 2. IFN-c secretion of HIV-C-DC-primed CD8
+ T cells. IFN-c secretion by CD8
+ T cells was measured by OPTEia (A) or by an IFN-c
secretion assay (B) following the second boost with DCs exposed to LPS or differentially opsonized HIV-1 preparations as indicated. iDC-primed CD8
+
T cells were used as negative control for IFN-c secretion. HIV-C-DCs but not HIV-DCs also induced IFN-c secretion by CD8
+ T cells following the third
boost (not shown). SEB-DCs induced high IFN-c secretion of CD8
+ T cells (A). In A, bars represent means (+SD) from four different CD8
+ T cell donors
stimulated with DCs exposed to differentially opsonized R5- or X4-tropic HIV (92BR030, BaL, NL4-3). In B, bars represent mean percentages of IFN-c-
secreting CD8
+ T cells after re-stimulation with iDCs or DCs exposed to HIV or HIV-C (BaL, 92BR030). The IFN-c-secretion assay was performed with T
cells from 5 different donors and data were analyzed by unpaired Student’s t-test.
doi:10.1371/journal.ppat.1000891.g002
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+ T cells (Fig. 4). This result was verified seven times with cells
from different donors and different HIV-1 preparations (BaL,
92BR030, 93BR020, data not shown). In addition, the experi-
ments were performed with R5- (BaL) and R5X4- (93BR020)tro-
pic AT-2-inactivated HIV-1 preparations (Figure S2). Also AT2-
HIV-C-DC-primed CD8
+ T cells showed significantly lower p24
values (p=0.02) than AT2-HIV-DC-stimulated CD8
+ T cells.
Furthermore, in contrast to HIV-DC-CD8
+ T cells, HIV-C-DC-
boosted CD8
+ T cells also elicited antiviral activity, when
stimulated CD4
+ T cells were infected 3 days prior addition of
the specific CTLs, thus inhibiting an already on-going infection of
the CD4
+ T cells. Supplementary Figure S3 shows p24 ELISA
values taken from CD4/CD8 T cell supernatants 5 and 9 days
post addition of the various CTLs to the already 3 days pre-
infected CD4
+ T cells.
Complement opsonization triggered activation and
proliferation of FV-specific CD8
+ T cells by virus-loaded
bmDCs
To investigate the role of C-opsonization in the induction of CD8
+
T cell responses in vivo, FV infection of mice was chosen as a model.
First, we confirmed that opsonization of F-MuLV with complement
enhanced infection of DCs as observed with HIV [14,16]. For this, F-
MuLV was incubated in vitro in normal mouse serum (NMS) to
deposit C3-fragments on the viral surface. Similarly to HIV, C3-
deposition was detected by virus capture assay (VCA) (data not
shown). Next, we performed infection experiments of mouse bone
marrow-derived DCs (bmDCs) with differentially opsonized F-MuLV.
Non- and C-opsonized F-MuLV productively infected bmDCs, but
significantly higher virus levels were obtained from culture superna-
tants of DCs infected with F-MuLV-C (data not shown).
Figure 3. Specificity and degranulation of HIV-C-DC-primed CTLs. (A) Analysis of the specificity of the in vitro generated CTLs by
tetramer analyses. Dead cells were excluded from analyses by 7-AAD staining and FACS plots were gated on CD8
high T cell populations. The panel
of dot plots shows the specificity by SLYNTVATL-PE tetramer staining (HLA-A02). In A, the top line (CD8
+ T cells) refers to what the cells were primed
with. For negative controls CD8
+ T cells were primed with cytokine-stimulated mDCs and re-stimulated with the HIV(HLA-A02)-specific peptide P1
(Control (mDCs)). As expected, these controls showed only low reactivity with the tetramer (1.5%). Also HIV-hiC-DC-primed CD8
+ T cells did not
recognize the tetramer (HIV-hiC(X4), 0.1%). The percentages of tetramer-positive CD8
+ T cells cells are outlined in the Figure and only HIV-C-DC-
primed CD8
+ T cells re-stimulated with P1 stained tetramer positive independently of the tropism of the virus used for DC stimulation (HIV-C(X4), HIV-
C(R5X4), HIV-C(R5)). 1.1% of HIV-C-DC-CD8
+ T cells re-stimulated with the control peptide P2 (HIV-C(X4)-P2) were SLYNTVATL-positive comparable to
mDC-primed CD8
+ T cells (HIV-C(X4)-P2). This figure shows a representative tetramer analysis from one donor and three different virus strains (NL4-3,
93BR020, 92BR030). Tetramer analysis was performed 4 times. (B) Degranulation of HIV-C-DC-primed CTLs. Degranulation was measured by
detection of cell surface CD107a after four hours of stimulation with specific peptides as indicated. Cells were gated on live, CD8
high populations. SEB-
stimulated mDC- or HIV-C(R5)-primed CD8
+ T cells were used as positive control for degranulation. The top line (CD8
+ T cells) refers to what the cells
were primed with and the bottom line (Addition of) to what they were stimulated with (SEB or peptide P1) and the percentages of CD107a-positive
cells are outlined in the figure. Beside SEB, only HIV-C-DC-primed CD8
+ T cells degranulated upon specific stimulation with P1 independently on the
tropism of the virus used (HIV-C(X4)/P1, HIV-C(R5X4)/P1, HIV-C(R5)/P1). Degranulation was measured concomitantly with tetramer analysis and
repeated 4 times.
doi:10.1371/journal.ppat.1000891.g003
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or C-opsonized F-MuLV to activate transgenic CD8
+ T cells
expressing a T cell receptor specific for an FV gag peptide (TCRtg
CD8
+ T cells) in vitro [34]. Co-culture of 1610
6 TCRtg CD8
+ T
cells with 1610
6 bmDCs exposed to 1000 FFU F-MuLV
significantly induced expression of the early activation marker
CD69 on CD8
+ T cells, when compared to control DCs (Fig. 5A).
CD8
+ T cell activation was significantly enhanced when FV-
specific CD8
+ T cells were co-cultured with bmDCs loaded to C-
opsonized F-MuLV (Fig. 5A, left). In addition to CD69, CD25 on
F-MuLV-C/bmDC-activated CD8
+ T cells was also expressed
(Fig. 5A, middle). Control OVA-specific OT-1 CD8
+ T cells were
not activated by either F-MuLV- or F-MuLV-C-loaded bmDCs
indicating that antigen specificity was required for stimulation
(Fig. 5A, right).
To study proliferation of FV-specific CD8
+ T cells induced by
virus loaded bmDCs, isolated FV-specific TCRtg CD8
+ T cells
were stained with CFSE prior to co-culture with bmDCs. We
found that after 4 days of co-culture both non- and C-opsonized F-
MuLV-loaded bmDCs induced proliferation of FV-specific CD8
+
T cells. However, the proliferation of CD8
+ T cells induced by F-
MuLV-C loaded bmDCs was more pronounced (Fig. 5B).
Spleen DCs (sDCs) isolated from FV-infected C3-deficient
mice show a reduced capacity to induce FV-specific CTLs
To determine whether complement played a role in DC-
mediated antigen presentation to CD8
+ T cells in vivo,w e
investigated B6 wt mice and complement component 3-deficient
mice (B6 C3
2/2) infected with FV. As expected from previous
results [22], a significant proportion of splenic CD11c
+ DCs
(sDCs) were infected at 4 days post infection (dpi) (Fig. 6A) as
determined by flow-cytometry using mAb clone 34, which
specifically stains F-MuLV glycosylated Gag protein expressed
on the surface of infected cells. In contrast, there was no significant
infection of sDCs from B6 C3
2/2 mice. Next, we isolated CD11c
+
sDCs from FV-infected B6 and B6 C3
2/2 mice after 4 dpi
allowing us to investigate their ability to stimulate FV-specific
TCRtg CD8
+ T cells in vitro. Compared to DCs from infected wt
mice, DCs from infected C3
2/2 mice had a significantly decreased
capacity to activate virus-specific CTLs as determined by the
expression of the activation markers CD69 and CD25 on the
CD8
+ T cells (Fig. 6B; expression of CD69, left panel; dual
expression of CD69 and CD25, right panel). Thus C3 was
important for the infection of DCs in vivo, and for their ability to
present antigen to CD8
+ T cells.
Pronounced FV-infection in C3-deficient mice
To determine if the activation and proliferation of virus-specific
CD8
+ T cells was impaired in C3-deficient mice, splenic CD8
+ T
cells were stained with tetramers. We observed a significantly
reduced proportion of tetramer positive CD8
+ T cells in the C3-
deficient mice compared to wt (Fig. 7A). Furthermore, there was
significantly reduced expression of the activation-induced isoform
of CD43 on CD8
+ T cells (Fig. 7B). Since previous results
indicated that CD8
+ T cells are critical for recovery from FV
infection [23], it was expected that impaired CD8
+ T cell
responses in C3-deficient mice would exacerbate FV infection.
Indeed, there were significantly higher proportions of infected
spleen cells in B6 C3
2/2 mice at 7 dpi compared to B6 wt animals
(Fig. 7C). These data indicated the importance of C3 for the
Figure 4. HIV-C-DC-primed CD8
+ T cells elicit antiviral effects. Inhibition of HIV p24 production by infected autologous CD4
+ T cells was
monitored after incubation with variously stimulated CD8
+ T cells. Mean p24 values of triplicates (+SD) from one donor on day 11 post addition of
HIV-specific CD8
+ T cells to NL4-3-incubated CD4
+ T cells are shown. Inhibition by HIV-C-DC-primed CD8
+ T cells was significantly greater than CD8
+ T
cells primed with non-opsonized HIV (p=0.0085). Similar results were obtained with cells isolated from 7 different donors using R5-, X4- and R5X4-
tropic viral isolates, BaL, 92BR030, 92UG037, NL4-3, 93BR020 (data not shown). A summary of all data in one graph was not feasible due to donor- and
virus strain-dependent differences in the infection efficiency, therefore p24 values of one representative donor is shown in this figure.
doi:10.1371/journal.ppat.1000891.g004
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activation and proliferation of CD8
+ T cells.
Discussion
Previous studies have demonstrated the involvement of comple-
ment in induction of an efficient CTL response against different
viral infections [10–12], but the mechanism by which complement
affected CTL responses was not elucidated. Our results illustrate an
important role for complement in facilitating antigen presentation
by DC’s to stimulate the activation, expansion, and differentiation
of retrovirus-specific CD8
+ Tc e l l sin vitro and in vivo. The results
indicate that complement serves as endogenous adjuvant for DC-
induced CTL responses against retroviruses. HIV-specific CTLs
generated in vitro by repeated prime-boosting with HIV-C-exposed
DCs were able to secrete IFN-c, de-granulated upon stimulation
with an HIV-specific HIV-peptide and CD3/CD28 engagement
[24] and elicited antiviral activity against HIV-infected autologous
CD4
+ T cells. These CTL priming properties were induced to a
much lesser extent by DCs loaded with non-opsonized HIV.
Infection of DCs was not the sole pre-requisite for the generation of
specific CTLs, since AT-2-inactivated HIV-C-DCs induced a
Figure 5. Complement enhances F-MuLV infection of bmDCs and induces activation and proliferation of FV-specific CD8
+ T cells by
virus-loaded DCs. (A) Bars indicate mean percentages of CD8
+ T cells expressing activation markers following stimulation as indicated on the X axis
(expression of CD69, left panel; dual expression of CD69 and CD25, middle and right panels). The left two panels show data from virus-specific CD8
+ T
cells while the right panel shows data from non-specific (OT-1) negative control cells. Data were analyzed by unpaired students t-test, n=10. (B) CFSE
dilution as measured by flow cytometry was used to analyze proliferation of TCRtg CD8
+ T cells in response to variously loaded DCs. Data are from
one representative of three independent experiments.
doi:10.1371/journal.ppat.1000891.g005
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+ T cell proliferation, too, and these were also able to elicit
antiviral activity against HIV-infected CD4
+ Tc e l lt a r g e t s .
Experiments using the FV model also revealed antigen-specificity
and the enhancing role of complement for DC-mediated CTL
induction both in vitro and in vivo.
The unique role of DCs in priming naı ¨ve CD8
+ T cells in
response to exogenous cell-associated as well as endogenously
synthesized Ags has been demonstrated [25,26]. With regard to
endogenously synthesized antigens, DCs infected with LCMV
elicited strong CTL responses, while LCMV infected macrophages
Figure 6. Spleen DCs from FV-infected C3-deficient mice show an impaired capacity to induce FV-specific CTL. (A) Infection of CD11c
+
spleen DCs were analyzed by flow-cytometry from non- and FV-infected B6 wt and C3
2/2 mice at 4 dpi by expression of viral glycosylated gag
protein using mAb clone 34. (B) Isolated sDC from non-infected controls (B6 control and B6 C3
2/2 control) and FV-infected (B6 4 dpi and B6 C3
2/2
4 dpi) animals were co-cultured with FV-specific TCRtg CD8
+ T cells for 24 hours and the activation of FV-specific CTLs was determined by measuring
cell-surface expression of CD69 and CD25 on TCRtg CD8
+ T cells (expression of CD69, left panel; dual expression of CD69 and CD25, right panel). Data
were analyzed by unpaired Student’s t-test.
doi:10.1371/journal.ppat.1000891.g006
Figure 7. Pronounced FV-infection in C3-deficient mice correlates with a lower frequency of FV-specific CTLs. B6 wt and B6 C3
2/2
mice were infected with 10000 SFFU of theFV-complex. (A) Splenic CD8
+ T cells were analyzed for FV specificity using gag-specific tetramers. (B)
Tetramer positive CD8
+ T cells were analyzed for expression of the effector cell marker CD43. (C) FV-infection of spleen cells was monitored by FACS
analysis using mAb clone 34. Data were analyzed by unpaired Student’s t-test.
doi:10.1371/journal.ppat.1000891.g007
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depletion of CD11c
+ DCs significantly decreases the frequency of
virus-specific CTLs in FV-infected mice [27]. Infection of DCs
and the presentation of endogenously synthesized viral antigens
processed through the MHC class I pathway might be important
during acute viral infection to prime naive CD8
+ T cells. In line
with these observations HIV-C incubation of DCs resulted in
enhancement of direct infection of the APCs compared to non-
opsonized HIV [14]. Thereby HIV-C-infected APCs could
process the endogenous Ags directly through the classic MHC
class I processing pathway and thus prime naı ¨ve CD8
+ T cells and
induce a virus-specific CTL response. Similarly to HIV,
complement-opsonized FV targeted mouse CD11c-positive den-
dritic cells more efficiently in vitro and in vivo, which resulted in a
more pronounced induction of virus-specific CTLs. Our data
strongly support a role for C-opsonization of retroviruses to
enhance infection of DCs and therefore facilitate the generation of
virus-specific CTLs. This hypothesis is further supported by the
reduced FV infection of DCs in C3-deficient mice and the reduced
induction of FV-specific CD8
+ T cells by DCs derived from FV-
infected C3-deficient mice. The involvement of neutralizing Abs
produced by B cells has been shown to be important in the control
of FV infections [17,28]. Despite C3-deficiences have been
demonstrated to have an impact on the maintenance of efficient
B cell response as early as 7 dpi, a dominant role an impaired
neutralizing B cell response in the elevated FV infection observed
in C3-deficient mice is rather unlikely.
Besides presentation of endogenous antigen a more efficient
cross-presentation of incoming complement-opsonized virus could
be initiated without infection of the DCs. CTLs generated by AT-
2-HIV-C-exposed DCs elicited antiviral activity against HIV-
infected target cells and the observed albeit weaker proliferation of
the CD8
+ T cells by repeated addition of AT-2-HIV-C-loaded
DCs indicates a combination of infection and cross-presentation
with respect to the effective CD8
+ T cell response mediated by
HIV-C-DCs.
To exclude that the CD8
+ T cell induction is not due to
triggering of DCs through CRs by complement itself, the
specificity of the HIV-C-DC-primed CTLs was confirmed using
peptide-tetramers and by HIV-specific lytic de-granulation and
antiviral activity against autologous HIV-infected CD4
+ T cells.
The antigen-specificity of C-mediated CTL induction by DCs was
further verified by using the FV model, since OVA-specific OT-1
T cells were not activated by F-MuLV- or F-MuLV-C-loaded
bmDCs. Thus, compared to non-opsonized virus, C-opsonized
virus activated DCs more efficiently to induce antigen-specific
CTLs for both, HIV and FV. Our results indicate an improved
processing of C-opsonized antigens due to putative binding to
either CR3 (CD11b/CD18) or CR4 (CD11c/CD18), which are
both expressed on DCs and may represent candidates for the
attachment of C-opsonized pathogens. Very recently, Castro et al.
[29] demonstrated that targeting Ags to CD11c, the %-chain of
CR4, on DCs exerted uniquely effective properties to generate
both CD4
+ and CD8
+ T cell responses, and suggested CD11c
targeting as efficient vaccination approach for protection against
tumor development. Furthermore, adenylate cyclase toxin (CyaA)
of Bordetella pertussis, which is targeting CD11b/CD18 (CR3)-
expressing cells, was successfully used to deliver CD8
+ T cell
epitopes for OVA as well as LCMV to induce specific CTL
responses [30–32]. In contrast, CR3 ligation was also suggested to
be associated with suppression of the stimulatory capacity of DCs
and to provide a ‘non-danger’ signal to the cells, but in this
particular study, CR3 was cross-linked via an anti-CR3 Ab rather
than using a pathogen [33]. Skoberne et al. [34] suggested that
under steady-state conditions, signaling via CRs makes DCs
tolerogenic, which however, can be overcome by a significant
inflammatory stimulus such as an infection. As observed in our
experiments with DCs and naı ¨ve CD8
+ T cells, C-opsonization of
HIV/FV triggered an effective CTL response, which might be due
to using a pathogen instead of an Ab to cross-link either CR3 or
CR4 on the cell surface of DCs.
Although other antigen presenting cells expressing complement
receptors like B cells and CD11b-positive monocytes/macrophag-
es might be also involved in the generation of an antiviral CTL
response in a complement dependent manner [35,36], a study
investigating the effect of DC-depletion on the induction of
primary CTL responses in LCMV infection implied a crucial role
of DCs in primary CTL response [26]. Despite we could not
provide direct evidence, our in vitro and in vivo data suggest a link
between complement and dendritic cells in the induction of
retrovirus-specific CTLs.
To summarize, our in vitro and in vivo experiments indicate that
HIV/FV potently activate DCs in a complement-dependent way
to generate cellular immune responses. Aside from induction of
retrovirus-specific CTLs by DCs in a complement-dependent
manner, other CTL-generating mechanisms may act in concert,
since the FV-specific CTL response does not completely disappear
in C3-deficient mice. Nevertheless, our data emphasize an
enhancing role of complement for the CTL- stimulatory capacity
of DCs against retroviruses like HIV or FV. Understanding the
exact interplay between differentially opsonized retroviral particles
and APCs is of prime importance for DC-based vaccination
strategies against retroviral infections.
Materials and Methods
Mice
Experiments were conducted using 3- to 6-month-old female
C57BL/6 (B6) mice. B6 C3 knock-out (C3
2/2) and FV-specific T
cell receptor (TCR) transgenic (Tg) mice [37], carrying a TCR
transgene that recognizes the gag leader peptide of FV [38], were
also used. All mice were bred and maintained free of specific
pathogens in the animal facility at the Department of Hygiene,
Microbiology and Social Medicine, Section of Virology, In-
nsbruck, Austria. Mice were treated in accordance with the
guidelines of the ‘‘European Convention for the Protection of
Vertebrate Animals used for Experimental and other Scientific
Purposes’’ and the Austrian law. Animal experiments were
approved by the ethics committee of the Austrian Federal Ministry
of Science and Research (BMWF-66.011/0081-II/10b/2008 and
BMWF-66.011/0039-C/GT/2007).
Virus propagation, purification and opsonization
Virus propagation and purification were performed as described
[14]. Virus strains were obtained by the NIH-AIDS (available
through WHO depositories) and following strains were used: BaL,
92UG037, 92BR030 (all R5), 93BR020 (R5/X4), NL4-3 (X4).
Ultracentrifuged, concentrated virus was opsonized in 200ml with
medium alone (HIV), heat-inactivated (thereby complement-
inactivated) normal human serum (NHS) (HIV-hiC), or NHS as
source for active complement (HIV-C). Subsequent to opsoniza-
tion the different preparations were washed with 1 ml RPMI1640
w/o supplements (RPMI) and the virus was pelleted by
ultracentrifugation. The virus was re-suspended in 200ml RPMI,
aliquoted and the presence of C3 fragments or IgGs on the viral
surface was confirmed by a virus capture assay (VCA) as shown in
Supplementary Figure S1A. IgGs on the viral surface were also
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tions with FcRs expressed on DCs.
FV-B complex was obtained as 10% spleen homogenate of
BALB/c mice 14 days post infection (dpi) and stored at 280uC.
Virus preparations were thawed immediately before infection,
centrifuged to pellet cell debris and diluted in phosphate-buffered
saline (PBS). For all in vivo infection experiments, mice were
injected intravenously with 10000 spleen focus-forming units
(SFFU) of FV-complex in 0.3 ml PBS. Virus stocks were free of
lactate dehydrogenase-elevating virus.
F-MuLV stocks for in vitro opsonization were generated in
permissive Mus dunni cells. Virus containing cell-culture superna-
tants (SNs) were stored at 280uC until use. F-MuLV was
opsonized in the presence of normal mouse serum (NMS) (as
source of complement) at a dilution of 1:10 for 60 minutes at 37uC
(F-MuLV-C). As controls, F-MuLV incubated in medium alone or
in heat-inactivated NMS (F-MuLV) was used. To remove NMS,
virus was ultracentrifuged (230006g, 2 hrs, 4uC) and the virus
pellet was resuspended in medium. To confirm the opsonization
pattern of the viruses, F-MuLV-C, and non-opsonized F-MuLV
were applied in a VCA as previously described for HIV [39]. Real-
time RT-PCR using FV-specific primers and fluorescently labelled
Taq-Man probe was used to determine the amount of F-MuLV.
Since experiments using non-opsonized and heat-inactivated
serum-opsonized virus preparations provided the same results, we
decided to show only the results from non- opsonized HIV/F-
MuLV.
Generation of human monocyte-derived DCs and
isolation of human CD4
+ and CD8
+ T cells
Monocytes were isolated from blood of normal healthy donors
by using human CD14 MicroBeads (Miltenyi Biotec), according to
the manufacturer’s instructions. DCs were generated and analyzed
as described [14]. B cells were depleted from PBLs using CD19
Pan B DynabeadsH (Dynal). Subsequently, CD4
+ (.95% purity)
and CD8
+ (.94% purity) T cells were bead-purified and used with
autologous DC’s for the in vitro experiments. To avoid non-
specific stimulation of the cells, all experiments were performed in
the presence of human AB serum (IgG low, PromoCell) instead of
FCS. Aliquots of DCs and T cells were frozen for boosting and
rather functionality tests.
Prime-boost experiments
Day 5 iDCs were stimulated with a cytokine-cocktail (IL-1b, IL-
6, PGE2, TNF-a, IL-4, GM-CSF) for 24 hrs and then transferred
into 96-well U-plates at a density of 10
4/100 ml. DCs from all
donors were loaded with 3 to 4 non- (HIV), complement-
inactivated (HIV-hiC) or complement-opsonized (HIV-C) R5-,
R5X4- and X4-tropic HIV strains for 3 hrs. DCs were exposed to
25 ng p24/ml of the differentially opsonized HIV (independent on
using live or AT2-inactivated HIV-preparations). As a positive
control for T cell proliferation, DCs were exposed to 1 mg/ml of
the superantigen Staphylococcal Enterotoxin B (SEB, Sigma) for
the same time-period. As additional controls iDCs and/or cytokine
cocktail-stimulated mature DCs (mDCs) were included in the
experimental settings. All tests were performed in triplicates. The
cells were thoroughly washed and non-stimulated, naı ¨ve CD8
+ T
cells were added to the primed DCs at a ratio 3:1. 25 U/ml IL-2
was added after 4 days and after another 4 days the T cells were
again boosted with loaded DCs. This procedure was repeated 3
times and the CD8
+ cells were analyzed for expansion, IFN-c
secretion, and functionality. HIV-induced proliferation of T cells
was analyzed by FACS and IFN-c secretion was detected using an
IFN-c OPTEiaH kit according to the manufacturer’s instructions
(BD Biosciences) and in parallel an IFN-c secretion assay
(Miltenyi). The IFN-c Secretion Assay enabled the sensitive
detection and analysis of human IFN-c-secreting cells by catching
secreted IFN-c on the CD8
+ T cell surface by an immobilised IFN-
c-catch reagent. The CD8
+ T cells were then boosted by loaded
DCs and incubated at 37uC for 48 hrs. The secreted IFN-c binds
to the IFN-c catch reagent on the cell surface of positive, secreting
cells, which are subsequently labeled with an anti-IFN-c antibody
for sensitive detection by flow cytometry. The time point (48 hrs)
for measurement of IFN-c secretion turned out to be optimal for
HIV-/HIV-C-DC-CD8
+ T cells, but not for SEB-stimulated cells,
which are recommended by the manufacturer to measure after an
incubation period of 3–16 hrs. To perform tetramer analyses and
cytotoxicity tests, T cells were expanded with the CD3/CD28 T
cell expander (Dynal) according to the manufacturer’s instructions
following the third priming with loaded DCs.
CD107a mobilization assay
Expanded CD8
+ T cells were re-stimulated with CD3/CD28
beads and appropriate HIVgag peptides (P1: SLYNTVATL+CR-
QILGQLQPSLQTG [HLA-A02]), and control P2: WMTN
NPPIPVGEIYK [HLA-A11/B035/Cw07]) in the presence of
FITC-conjugated CD107a mAb [20] for 4 hrs at 37uC. The
compatibility of epitopes and viruses used in these experiments
(92BR030, 93BR020, NL4-3) was analyzed by the Epitope Location
Finder (ELF) (http://www.hiv.lanl.gov/content/sequence/ELF/
epitope_analyzer.html). In all experiments SEB (1 mg/ml; Sigma-
Aldrich, St. Louis, MO) was used as a positive control for
degranulation [21], and as negative control mDC-expanded CD8
+
T cells were stimulated with the HIV-specific peptide P1 to control
for spontaneous expression of CD107a [6]. FACS analyses were
performed with additional markers (7-AAD, CD8-APC).
Functionality of in vitro generated cytotoxic T cells
To further determine the functionality of the in vitro generated
HIV-specific CTLs, frozen autologous CD4
+ T cells were thawed,
washed, and stimulated with CD3/CD28 beads (Dynal) in
presence of IL-2 (100 U/ml). Pre-stimulation of the CD4
+ T cells
with CD3/CD28 was necessary to induce the up-regulation of
CCR5. The in vitro primed and expanded CTLs were added to o/
n HIV-incubated CD4
+ T cells. In some experiments, primed
CD8
+ T cells were added after 3 days of infection of CD4
+ T cells
to see, if they can block an already ongoing infection. A reduction
in virus production assessed by p24 ELISA on several days post
addition of the expanded CTLs indicated an indirect confirmation
of their functionality. By using this assay we were in addition able
to circumvent the problem of the unknown HLA-type of the
majority of the donors. This indirect confirmation of the
functionality was performed with expanded CTLs from seven
donors primed and boosted with HIV-exposed DCs.
In vitro infection of bmDCs with differentially opsonized
F-MuLV
BmDCs were generated as described by Inaba et al. [40] with
some modifications. Briefly, 2610
6 bone marrow cells were
cultivated in 10 ml of DC medium (RPMI 1640 supplemented
with 10% FCS, 2 mM L-glutamine, 500 nM 2-ME, 100 U/mL
penicillin/streptomycin and 1000 U/ml mouse GM-CSF) in Petri
dishes for three days at 37uC. 10 ml of fresh DC medium was then
added and cells were cultured for another 3 days. On day 6 non-
adherent cells were removed, washed and cultivated in fresh 20 ml
DC medium. Non-adherent cells obtained after 8 days displayed a
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revealed by flow cytometry.
Co-culture of F-MuLV-loaded DCs with FV-specific TCRtg
CD8
+ T cells
For co-culture experiments, 1610
6 bmDCs were loaded with
1000 focus-forming units (FFU) F-MuLV. Since complement-
opsonization might influence infectivity, bmDCs were loaded with
equivalent amounts of F-MuLV-C RNA as determined by real-
time RT-PCR. As controls, non-loaded bmDCs were used. After
24 hrs of incubation with differentially opsonized F-MuLV,
bmDCs were washed twice and co-cultured with 1610
6 FV-
specific CD8
+ T cells isolated from the spleens of FV-specific
TCRtg mice using the BD IMag CD8 T Lymphocyte Enrichment
Set (BD Pharmingen) according to the manufacturer’s instructions
(purity .95% as determined by FACS). After 24 hrs of co-culture,
activation of FV-specific CD8
+ T cells was analyzed by flow
cytometry. To study proliferation, isolated CD8
+ T cells were
labeled with CFSE prior to co-culture and the dilution pattern of
CFSE was analyzed by FACS after 4 days.
To test whether DCs confronted with FV opsonized under in
vivo conditions exert similar effects on FV-specific CD8
+ T cells
as bmDCs loaded with in vitro opsonized F-MuLV, B6 wild-type
(wt) and B6 C3
2/2 mice were infected i.v. with 10000 SFFU of
the FV-complex. Single spleen cell suspensions from mice at
4 dpi were used to purify CD11c
+ DCs using CD11c MicroBe-
ads (Miltenyi) according to the manufacturer’s instructions
(purity ,90% of CD11c
+ cells). 1610
6 spleen DCs were then
co-cultured for 24 hours with 1610
6 FV-specific TCRtg CD8
+
T cells.
FV infectious center (IC)-assays
Serial dilutions from the culture SNs of F-MuLV infected
bmDCs were plated onto susceptible Mus dunni cells to detect
productive infection of bmDCs in vitro. Mus Dunni cells were
cultivated for 5 days, fixed with ethanol, stained with F-MuLV
envelope-specific mAb 720 [41], and developed with goat anti-
mouse peroxidase conjugate (DAKO) and with 3-amino-9-
ethylcarbazole (AEC) substrate to detect foci.
Tetramers and tetramer staining
To specifically characterise the generated CTLs, DCs and T
cells from an HLA-A02
+ donor were isolated. Following prime/
boosting and expansion, cells (10
5 cells/sample) were either
stimulated with specific immunodominant HIV-1 gag epitopes
P1 or P2 (see above). FACS analyses were performed with the
HLA-A02-specific tetramer (SLYNTVATL-PE [Coulter]) and
additional markers (7-AAD, CD8-APC).
To detect FV-virus-specific CD8
+ T cells from FV-infected
animals, 1610
6 spleen cells were stained with anti-mouse CD8
APC-labeled mAb (53-6.7, BD Pharmingen) and PE-labeled
MHC class-I H-2D
b tetramers specific for the immunodominant
GagL CTL epitope gPr80
gag85–93 (Beckman Coulter), for 15 min
at room temperature. The activated FV-specific CD8
+ T cells
were detected by co-staining with FITC-labeled anti-mouse CD43
mAb (1B11, BioLegend). Dead cells were excluded from analyses
(BD Pharmingen).
Cell surface staining
Expression of mouse cell-surface molecules was quantified
using following BD Pharmingen monoclonal antibodies (mAbs):
anti-CD8-APC, anti-CD69-PE, anti-CD25-FITC, CD11b-PE,
CD11c-APC. To detect FV-infected cells, spleen cells from FV-
infected mice were stained with biotinylated mAb clone#34.
Binding of biotinylated mAb 34 was detected with APC-
conjugated streptavidine (BD Pharmingen). For flow cytometry,
1610
6 cells were incubated with 1 to 5mg/ml mAb for 30 min at
4uC, washed twice in PBS/1% FCS, and measured on a
FACSCanto II (BD). Dead cells were again excluded using 7-
AAD. Data were analyzed using FACS Diva (BD).
Statistical analysis
Differences between samples were analyzed by the GraphPad
prism software. P values p,0.05 in the unpaired Student’s t-test
were scored as significant.
Supporting Information
Figure S1 Figure S1A. Virus capture assay (VCA) of differentially
opsonized HIV-preparations. HIV was opsonized with medium
alone (HIV), normal human serum (NHS) as source of
complement (HIV-C), or complement-inactivated NHS (HIV-
hiC). Following opsonization the virus preparations were
washed, centrifuged at 14000 rpm/90min/4uC, and the pellet
was resuspended in 200ml RPMI. The opsonization pattern was
determined by VCA using an anti-human C3c/C3d-, IgG or an
anti-mouse IgG as control. As expected no C3-fragments or
IgGs were found on the HIV and HIV-hiC virus preparations.
C3 fragments, but no IgGs were detected on HIV-C. Figure S1B.
DCs loaded with complement-inactivated NHS do not induce proliferation
of CD8
+ Tc e l l s .Percentages of CFSE- [proliferated]/CD8
+ T
cells of SEB-, HIV-, HIV-C-, or HIV-hiC-DC-primed CD8
+ T
cells from one representative virus preparation are outlined in
this Figure. Only SEB- and HIV-C-DCs induced high
expansion of CD8
+ T cells, while only low T cell proliferation
was observed upon stimulation with HIV-, or HIV-hiC-DCs.
Only low T cell expansion was also detected when priming the
cells with DCs loaded with IgG-opsonized HIV (not shown). All
experiments were performed with DCs exposed to HIV and
HIV-hiC. Since those preparations exerted similar effects in all
experiments and to simplify the terminology and figures, we
only showed HIV in all Figures.
Found at: doi:10.1371/journal.ppat.1000891.s001 (0.14 MB
PPT)
Figure S2 AT2-HIV-C-DCs exert an antiviral effect upon co-culture
with infected, autologous CD4
+ T cells. Expanded AT2-HIV-C-DC-
primed CD8
+ T cells proved to be functional upon addition to
infected, autologous CD4
+ T cells and significantly inhibited
productive infection compared to CD8
+ T cells primed/boosted
with AT2-HIV-DCs (p=0.02). Too, infection of CD4
+ T cells was
higher in co-cultures, where SEB-, mDC- or iDC-primed CD8
+ T
cells were added. This experiment was performed in triplicates
with 3 different AT2-inactivated HIV strains (BaL, 92UG037,
93BR020) and mean values are shown.
Found at: doi:10.1371/journal.ppat.1000891.s002 (0.12 MB
PPT)
Figure S3 Expanded HIV-C-DC-CD8
+ T cells exert an antiviral effect
on autologous CD4
+ TCs infected with HIV 3 days prior addition. An
already on-going infection of CD4
+ TCs (3 days pre-infected) was
inhibited by addition of HIV-C-DC-primed CD8
+ T cells as
shown by determining p24 values from the supernatants 5 and 9
days post addition of CD8
+ T cells. In contrast, HIV-DC-primed
CD8
+ T cells did not show an antiviral effect. This experiment was
performed in triplicates with cells from 2 donors and mean values
are given.
Found at: doi:10.1371/journal.ppat.1000891.s003 (0.11 MB PPT)
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